Sunday, December 22, 2024
type here...
- Advertisement -spot_img

TAG

Novo Nordisk

Bussiness

Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results

Admin -
Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough...
Bussiness

In weight loss battle, Novo and Lilly face growing offensive from licenced copies

Admin -
By Andrew Silver SHANGHAI (Reuters) - As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss...
Bussiness

In weight loss battle, Novo and Lilly face growing offensive from licensed copies

Admin -
(Corrects typographical error in headline.) By Andrew Silver SHANGHAI (Reuters) -As Novo Nordisk and Eli Lilly expand sales of their...
Bussiness

Regulatory conditions on Novo Holdings’ $16.5 billion Catalent deal fulfilled, companies say

Admin -
(Reuters) - All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had...
Bussiness

Regulatory conditions on Novo Holdings’ $16.5 billion Catalent deal fulfilled, companies say

Admin -
(Reuters) - All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had...
Bussiness

Novo Nordisk CFO says 2025 sales could see high-teens percentage growth

Admin -
LONDON (Reuters) - Novo Nordisk's sales growth next year could be in the high teens in percentage terms, Chief Financial...
Bussiness

Novo Nordisk narrows 2024 guidance range, Q3 in line with expectations

Admin -
COPENHAGEN (Reuters) -Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed...
Bussiness

Novo Nordisk Shares Seen Outpacing Lilly’s After Summer Stumble

Admin -
(Bloomberg) -- Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the...
Sports

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings’ buyout

Admin -
(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired...
Bussiness

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings’ buyout

Admin -
(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired...
Bussiness

Novo says Ozempic ‘very likely’ to be on 2027 Medicare negotiation list, Bloomberg News reports

Admin -
(Reuters) - Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations,...
Sports

Ozempic shortages in EU will not affect all member states – Novo Nordisk

Admin -
By Maggie FickLONDON (Reuters) - Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter...

Latest news

- Advertisement -spot_img

© Thestarnewstoday. All rights reserved.

About Us

Popular Category

Latest News